씨지온콜로지(CGON)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $73.47 (-2.84%), 시가총액 $6.13B, 52주 최저~최고 $23.95 ~ $74.00.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent;
씨지온콜로지의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
씨지온콜로지의 현재 주가는 $73.47 (-2.84%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
씨지온콜로지의 시가총액은 약 $6.13B입니다.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's prod